Global Radioimmunotherapy Market, Dosage, Price and Clinical Pipeline Outlook 2022

Download Sample

 

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink:https://www.kuickresearch.com/report-global-radioimmunotherapy-market,-dosage,-price-and-clinical-pipeline-outlook-2022.php

 

Table of Contents

 

1. Cancer Radioimmunotherapy – Amalgamation Therapy for Elevated Efficacy

  1.1 Prologue to Cancer Radioimmunotherapy

  1.2 History and Evolution of Cancer Radioimmunotherapy

2. Radioimmunotherapy – An insight into its Need and Efficacy

  2.1 High Unmet Medical Needs and Failure of Conventional Cancer Therapeutics

  2.2 Targeted Therapy for Higher Efficacy

  2.3 Superiority of Radioimmunotherapy over Other Cancer Therapeutics

3. Features of Radioimmunotherapy

  3.1 Approved Benefits Associated with Radioimmunotherapy

  3.2 Radioimmunotherapy using Monoclonal Antibodies

4. Components of Radioimmunotherapy

  4.1 Tumor Antigens – Potential Targets for Monoclonal Antibodies

  4.2 Radionuclides

  4.3 Antibodies – Key Components in Radioimmunotherapy

5. Radioimmunotherapy – Principle and Action

6. Clinical Status of Radioimmunotherapy in Various Cancer Therapy

  6.1 Non Hodgkin Lymphoma (NHL)

  6.2 Follicular Lymphoma

  6.3 Solid Tumors

  6.4 Breast Cancer

  6.5 Ovarian Cancer

  6.6 Osteosarcoma

  6.7 Neuroblastoma

  6.8 Prostate Cancer

7. Emerging Opportunities and Avenues in the Radioimmunotherapy Segment

  7.1 Immune Checkpoint Inhibitors and Radioactive Iodine in Cancer Radioimmunotherapy

  7.2 Nanotechnologically Created Radiotracer: For Efficient Delivery of Radioactivity in Tumor Cells

8. Radioimmunotherapy Market – Dosage and Price Analysis of Monoclonal Antibodies involved

 8.1 Ibritumomab tiuxetan (Zevalin) and Rituxanandndash; Dosage and Price Analysis in Follicular B-cell Non-Hodgkin Lymphoma

  8.2 Zevalin and Rituxan: Therapy Cost Analysis

  8.3 Comparative Cost Analysis of Radioimmunotherapy with Traditional Cancer therapy Methods

  8.4 Tositumomab and iodine I 131 Tositumomab (Bexxar)

9. Market Performance and Trends in Radioimmunotherapeutics Segment

  9.1 Better Safety and Efficacy but Limited Growth Opportunity

  9.2 Decreasing Sales of Zevalin Threatening the Radioimmunotherapy Market

  9.3 Involvement of Blockbuster Therapeutics in Radioimmunotherapy to Ensure Stability in the Future

  9.4 Emerging Pattern of Radioimmunotherapy Drug Referrals

10. Radioimmunotherapy Monoclonal Antibodies Currently Under Development and Their Market Potential

  10.1 Epratuzumab

  10.2 Lintuzumab

  10.3 Labetuzumab

  10.4 Trastuzumab (Herceptin)

11. Antibodies in Radioimmunotherapy – Patent Analysis

12. Regional Analysis of the Radioimmunotherapy Market

  12.1 North America

    12.1.1 United States (US)

    12.1.2 Canada

  12.2 Europe

    12.2.1 Germany

    12.2.2 France

    12.2.3 United Kingdom (UK)

    12.2.4 Rest of Europe

  12.3 Asia – Pacific

    12.3.1 China and India

    12.3.2 Japan

    12.3.3 Australia

  12.4 Rest of the World

13. Global Radioimmunotherapy Market Driving Parameters

14. Radioimmunotherapy – Overcoming the Challenges and Shortcomings

15. Future Forecast and Perspective Regarding the Immunotherapy Segment

  15.1 Global Approval of Radioimmunotherapy to Enhance Market Growth in Future

  15.2 Radiopharmaceutical Market and its Impact on the Radioimmunotherapy market growth

  15.3 Other Market Propelling Factors

16. Global Radioimmunotherapy Clinical Pipeline by Company, Indication and Phase

  16.1 Global Radiopharmaceuticals Pipeline Overview

  16.2 Unknown

  16.3 Research

  16.4 Preclinical

  16.5 Clinical

  16.6 Phase-0

  16.7 Phase-I

  16.8 Phase-I/II

  16.9 Phase-II

  16.10 Phase-III

  16.11 Preregistration

  16.12 Registered

17. Competitive Landscape

  17.1 Bayer Healthcare Pharmaceuticals

  17.2 BioSynthema

  17.3 Clarity Pharmaceuticals

  17.4 Curasight

  17.5 Endocyte

  17.6 Immunomedics

  17.7 Molecular Insight Pharmaceuticals

  17.8 Nordic Nanovector

  17.9 PDL Biopharma

  17.10 Philogen

  17.11 RadioMedix

  17.12 Stella Pharma

  17.13 Telix Pharmaceuticals

 

 

Figure 1-1: Evolution of Radiopharmaceuticals and Radioimmunotherapy

Figure 2-1: Need for Radioimmunotherapy

Figure 4-1: Components or Radioimmunotherapy

Figure 4-2: Monoclonal Antibodies – Vital Target Sites in Immunotherapy

Figure 4-3: Antigen Target and Their Therapy Antibodies in Radioimmunotherapy

Figure 4-4: Development of a Radionuclide

Figure 4-5: Half Life of Various Radioimmunotherapy Nuclides

Figure 4-6: Tissue Penetration of Key Radionuclides Used in Immunotherapy (mm)

Figure 4-7: Monoclonal Antibody in Radioimmunotherapy

Figure 5-1: Fundamental Working Mechanism of Radioimmunotherapy

Figure 6-1: Global – Non Hodgkin Lymphoma Incidence and Mortality by Numbers, 2018

Figure 6-2: Clinical Efficacy- Rituximab v/s Zevalin Standalone Therapy (%)

Figure 6-3: Global – Ovarian Cancer Incidence (per 100,000 Females), 2018

Figure 7-1: Humanized Antibodies – High Efficacy due to decreased Immunogenecity

Figure 8-1: Zevalin – Overview of Dosage Schedule

Figure 8-2: Zevalin- Dosage (milliCurie/kg)

Figure 8-3: Zevalin – Cost Analysis (US$/ml), 2018

Figure 8-4: Rituxan – Dosage (mg/m2)

Figure 8-5: Rituxan – Cost Analysis (US$/ml), 2018

Figure 8-6: Dosage – Median Radiation Dosimetry(Y-90 Zevalin cGy /mCi)

Figure 8-7: Zevalin and Rituxan: Average Therapy Cost Analysis (US$), 2018

Figure 8-8: Comparative Cost Analysis: Radioimmunotherapy v/s Traditional Cancer Therapeutics

Figure 8-9: Overview – Ositumab Dosing Schedule in Non-Hodgkin Lymphoma

Figure 8-10: Tositumab and I 131 Tositumab- Dosage (mg/Session)

Figure 8-11: Radiation dosimetry in Bexaar Therapy

Figure 9-1: Global – Zevalin Sales by Year  (US$ Million), 2013-2016

Figure 9-2: Global – Rituxan Market Size (%), 2018

Figure 9-3: Global- Rituxan Sales (US$ Billion), 2015 and 2016

Figure 9-4: Global andndash; Tositumomab Referral Trend Analysis by Practice (%), 2018

Figure 11-1: Patent Status – Monoclonal Antibody in Radioimmunotherapy, 2018

Figure 12-1: Canada – Comparative Price Analysis, RIT v/s Non-RIT treatment Modality (US$), 2018

Figure 13-1: Driving Factors of the Radioimmunotherapy Segment

Figure 14-1: Challenging Aspects of the Radioimmunotherapy Market

Figure 15-1: Zevalin – Sales Future Forecast (US$ Million), 2016-2022

Figure 15-2:Rituxan – Future Sales Forecast (US$ Billion), 2016-2022

Figure 15-3: Probability of Radioimmunotherapy Market Growth (%), 2018

Figure 15-4: Global – Radioimmunotherapy Market Size by End User (%), 2018

Figure 16-1: Global – Radiopharmaceuticals Clinical Pipeline by Phase (%), 2018 till 2022

Figure 16-2: Global – Radiopharmaceuticals Clinical Pipeline by Phase (Number), 2018 till 2022